Home
Resource
Structure-activity relationships of small molecule direct inhibitors of Keap1-Nrf2 interaction
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(5.59 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Abed, Dhulfiqar Ali. Structure-activity relationships of small molecule direct inhibitors of Keap1-Nrf2 interaction. Retrieved from https://doi.org/doi:10.7282/T35T3PXF

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleStructure-activity relationships of small molecule direct inhibitors of Keap1-Nrf2 interaction
NameAbed, Dhulfiqar Ali (author); Hu, Longqin (chair); LaVoie, Edmond J. (internal member); Rice, Joseph E. (internal member); Chackalamannil, Samuel (outside member); Rutgers University; School of Graduate Studies
Date Created2018
Other Date2018-05 (degree)
SubjectMedicinal Chemistry, Molecular biology, Oxidative stress
Extent1 online resource (xiv, 268 p. : ill.)
DescriptionThe Keap1–Nrf2–ARE system represents a crucial antioxidant defense mechanism that protects cells against oxidative stress-related diseases and inflammation. Activation of this system leads to elevated expression of a variety of antioxidant defense proteins and enzymes important for protection against oxidative damage, inflammation and tumorigenesis. Targeting Keap1–Nrf2 protein–protein interaction (PPI) has become a promising therapeutic strategy for several oxidative stress conditions and inflammatory diseases including chronic kidney disease, pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD), and cancer chemoprevention. Several PPI inhibitors of Keap1–Nrf2 system have been reported; Tecfidera® is one of these inhibitors that is FDA approved for treatment of patients with relapsing multiple sclerosis. Inhibitors of Keap1–Nrf2 PPI are generally classified into direct and indirect inhibitors. Indirect inhibitors of Keap1–Nrf2 PPI are electrophilic species and can cause off-target side effects. Presently, scientists have been focusing on direct inhibitors of Keap1–Nrf2 PPI. In this work, we are focusing on the discovery of potent direct inhibitors of Keap1−Nrf2 PPI by performing a comprehensive structure-activity relationship (SAR) study in currently available scaffolds, or by designing new scaffolds. A fluorescence polarization (FP) assay has been used to evaluate the potency of synthesized compounds in vitro and cell-based assays have been used to test the most active compounds, resulting in the discovery of highly potent non-electrophilic Nrf2 activators. One of the best compounds discovered, 65v (LH835), has an IC50 of 144 ± 5 nM in the fluorescence polarization assay, and 1.7 ± 0.24 nM in a TR-FRET assay. Furthermore, we have demonstrated that the 65v (LH835) is an efficacious inducer of Nrf2 targeted genes in HepG2 C8 cells, exhibiting activity better than the well-known electrophilic activator, sulforaphane. Our direct inhibitors of Keap1–Nrf2 PPI could potentially be developed into drugs for the treatment of a number of oxidative stress-related diseases and conditions.
NotePh.D.
NoteIncludes bibliographical references
Noteby Dhulfiqar Ali Abed
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T35T3PXF
Languageeng
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.3
Rutgers University Libraries - Copyright ©2023